Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 14Nivolumab 13Sunitinib 12Axitinib 9cabozantinib 8belzutifan 8Ipilimumab 7Everolimus 5atezolizumab 4Sorafenib 4temsirolimus 3perifosine 3motexafin gadolinium 3Drug Therapy 3spartalizumab 2palbociclib 2liposomal doxorubicin 2lenvatinib 2entinostat 2ciforadenant 2belinostat 2avelumab 2Paclitaxel 2Immunotherapy 2G250 monoclonal antibody 2Fluorouracil 2Docetaxel 2Dexamethasone 2Cetuximab 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Neoplasms × Receptors, Vascular Endothelial Growth Factor × Clear all
NCT00076011 2012-06-26

Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

Pfizer

Phase 2 Completed
52 enrolled 9 charts
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡